Alpha 1a adrenergic receptor antagonists

Details Alpha 1a adrenergic receptor antagonists Alpha 1a adrenergic receptor antagonists

1998-06-17

2000-03-14

Shah, Mukund J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514326, 514369, 514376, 546194, 546209, 548228, 548230, 548183, 548188, 548189, C07D26306, C07D26304, C07D27704, C07D41312, A61K 3142

Patent

active

060373547

ABSTRACT:
This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

REFERENCES:
patent: 4049821 (1977-09-01), Funderburk, Jr.
patent: 4109005 (1978-08-01), Lunsford et al.
patent: 4226612 (1980-10-01), Pilgram
patent: 4250318 (1981-02-01), Dostert et al.
patent: 4254135 (1981-03-01), Walsh et al.
patent: 4505859 (1985-03-01), Poindexter
patent: 4661491 (1987-04-01), Regnier
patent: 4769371 (1988-09-01), Atwal
patent: 4847379 (1989-07-01), Atwal
patent: 4855301 (1989-08-01), Atwal et al.
patent: 4882431 (1989-11-01), Ishimitsu et al.
patent: 5023338 (1991-06-01), Ocain et al.
patent: 5124457 (1992-06-01), Ungemach et al.
patent: 5202330 (1993-04-01), Atwal et al.
patent: 5374637 (1994-12-01), Van Daele et al.
patent: 5547950 (1996-08-01), Hutchinson et al.
patent: 5565571 (1996-10-01), Barbachyn et al.
patent: 5668286 (1997-09-01), Yamada et al.
patent: 5719154 (1998-02-01), Tucker et al.
G. C. Rovnyak et al., "Dihydropyrimidine Calcium Channel Blockers. 4. Basic 3-Substitutued-4-aryl-1, 4-dihydropyrimidine-5-carboxylic Acid Esters. Potent Antihypertensive Agents", J. Med. Chem., 35(17), 3254-63 (1992).
K. S. Atwal et al., "Dihydropyrimidine Calcium Channel Blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Orally Effective Antihypertensive Agents", J. Med. Chem., 34(2), 806-11 (1991).
K. S. Atwal et al., "Dihydropyrimidine Calcium Channel Blockers. 2. 3-Slubstituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines", J. Med. Chem., 33(9), 2629-35 (1990).
K. S. Atwal et al., "Substituted 1,4-Dihydropyrimidines. 3. Synthesis of Selectively Functionalized 2-Hetero-1,4-dihydropyrimidines", J. Org. Chem., 54(25), 5898-907 (1989).
Chemical Abstracts No. 58:11360a: R. Merten et al., "Reaction of acylated aldehyde aminals with unsaturated hydrocarbons", Angew. Chem. 74, 866-71 (1962).
Derwent CPI Abstracts No. 90-041598, "Remedy for Dysuria", Abstract of JP01-319418, Nippon Chemifar (1990).
Derwent CPI Abstracts No. 87-027600, "New 1,3-oxazolidin-2-one derivatives", Abstract of JP61-286375, Nippon Chemifar (1987).
W. C. Wong et al., "Design and Synthesis of Dihydropyrimidines as Alpha 1a Adrenoceptor Selective Antagonists", Abstract No. MEDI 064, 215th ACS National Meeting, Dallas, TX (Mar. 29,--Apr. 2, 1998).
B. Lagu et al., "Design, Synthesis and Evaluation of Dihydropyrimidinones as Alpha 1a Selective Antagonists", Abstract No, MEDI 065, 215th ACS National Meeting, DAllas, TX (Mar. 29--Apr. 2, 1998).
D. Nagarathnam et al., "Design, Synthesis and Evaluation of Dihydropyrimidinones as Alpha 1a Selective Antagonists: 6. Synthesis and Structure-Activity Relationship of SNAP 6553 and Analogs", Abstract No. MEDI 066, 215th ACS National Meeting, Dallas, TX (Mar. 29--Apr. 2, 1998).
M. R. Marzabadi et al., "Design, Synthesis and Evaluation of Dihydropyrimidinones and Dihydropyrimidines as Alpha 1a Selective Antagonists: Modification of the Diarylpiperidine Moiety", Abstract No. MEDI 067, 215th ACS National Meeting, Dallas, TX (Mar. 29--Apr. 2, 1998).

Affiliated with

Also associated with

Rating

Alpha 1a adrenergic receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alpha 1a adrenergic receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha 1a adrenergic receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-169509